Equities analysts predict that Bausch Health Companies Inc. (NYSE:BHC) will announce $2.23 billion in sales for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Bausch Health Companies’ earnings. The lowest sales estimate is $2.19 billion and the highest is $2.27 billion. Bausch Health Companies posted sales of $2.21 billion during the same quarter last year, which would indicate a positive year over year growth rate of 0.9%. The firm is scheduled to report its next quarterly earnings report on Wednesday, February 23rd.
According to Zacks, analysts expect that Bausch Health Companies will report full year sales of $8.47 billion for the current year, with estimates ranging from $8.43 billion to $8.57 billion. For the next financial year, analysts anticipate that the company will post sales of $8.91 billion, with estimates ranging from $8.71 billion to $9.20 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that follow Bausch Health Companies.
Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Tuesday, November 2nd. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.07. Bausch Health Companies had a negative return on equity of 2,440.75% and a negative net margin of 13.85%. The business had revenue of $2.11 billion for the quarter, compared to analysts’ expectations of $2.15 billion.
Shares of NYSE BHC traded up $0.08 during mid-day trading on Friday, reaching $26.11. 1,280,183 shares of the company’s stock were exchanged, compared to its average volume of 3,088,960. The firm has a market capitalization of $9.37 billion, a price-to-earnings ratio of -7.96, a price-to-earnings-growth ratio of 1.45 and a beta of 1.56. Bausch Health Companies has a 52 week low of $18.49 and a 52 week high of $34.80. The firm has a 50-day moving average price of $27.66 and a two-hundred day moving average price of $28.69.
A number of hedge funds have recently made changes to their positions in BHC. Vanguard Group Inc. increased its stake in shares of Bausch Health Companies by 1.1% during the second quarter. Vanguard Group Inc. now owns 9,307,234 shares of the company’s stock valued at $272,887,000 after buying an additional 96,748 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Bausch Health Companies by 48.2% in the second quarter. Price T Rowe Associates Inc. MD now owns 7,850,573 shares of the company’s stock worth $230,179,000 after purchasing an additional 2,553,297 shares during the period. Laurion Capital Management LP grew its stake in Bausch Health Companies by 10.9% in the third quarter. Laurion Capital Management LP now owns 7,536,780 shares of the company’s stock worth $209,899,000 after purchasing an additional 741,378 shares during the period. Guardian Capital LP grew its stake in Bausch Health Companies by 13.7% in the second quarter. Guardian Capital LP now owns 4,907,407 shares of the company’s stock worth $144,175,000 after purchasing an additional 591,054 shares during the period. Finally, Miller Value Partners LLC grew its stake in Bausch Health Companies by 2.5% in the second quarter. Miller Value Partners LLC now owns 3,330,390 shares of the company’s stock worth $97,647,000 after purchasing an additional 79,969 shares during the period. Hedge funds and other institutional investors own 75.43% of the company’s stock.
About Bausch Health Companies
Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
Recommended Story: What is the cash asset ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.